Cosmos Holdings to Acquire LIFE NLB Portfolio of Bone Health Products that Target the Gastrointestinal Microbiome
Cosmos Holdings (Nasdaq:COSM) has announced an agreement to acquire LIFE NLB Ltd.'s product portfolio, which includes Bone-Vio® and Bone-X, aimed at enhancing bone health by targeting the gastrointestinal microbiome. This acquisition is positioned to establish Cosmos in the expanding osteoporosis drug market, valued at USD 13.36 billion and projected to grow at a CAGR of 6.83% to USD 20.17 billion by 2026. The Bone-Vio® product's clinical trial results are expected in 2023, highlighting its potential effectiveness in addressing osteoporosis.
- Acquisition of LIFE NLB's bone health products strengthens Cosmos' market position.
- Provides entry into the growing osteoporosis drug market, projected to reach USD 20.17 billion by 2026.
- Bone-Vio® targets the intestinal microbiome, which may improve absorption and bioavailability of bone health ingredients.
- Potential for new product development and research collaborations.
- Dependence on the success of the ongoing clinical trial for Bone-Vio®.
Acquisition will include all launched and under development bone health products
CHICAGO, IL / ACCESSWIRE / July 6, 2022 / Cosmos Holdings, Inc. ("the Company") (Nasdaq:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced that it has entered into an agreement to acquire LIFE NLB, Ltd.'s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome.
The intestinal microbiome has been proposed as a new therapeutic target for osteoporosis. It is believed to contribute to the integrity of the intestinal barrier and mineral absorption, which is strongly correlated with bone mass. Changes in the intestinal microbiome has been shown to lead to changes in the expression of cytokines and growth factors that affect the immune, endocrine, vascular and nervous systems, which in turn affect the regulation of differentiation and/or the functioning of bone cells. LIFE NLB'S Bone-Vio® product is a combination of calcium citrate, Vitamin D and prebiotics that target the microbiome. Bone-Vio® is currently being evaluated in a clinical trial with results of the trial expected to be published in 2023.
According to ReportLinker, the global osteoporosis drug market was valued at USD 13.36 billion in 2020 and is projected to grow at a CAGR of
Nikos Bardakis, founder of LIFE NLB, stated, "A key problem with most products on the market for bone health is inadequate absorption and bioavailability, as ingredients often do not effectively cross the intestinal barrier, and they typically exhibit low plasma concentration. We have designed our bone health products to ensure adequate absorption, maximizing the benefits of the contained ingredients. We look forward to working with Cosmos to further research and develop new and innovative products targeting bone health."
Greg Siokas, Chief Executive Officer of Cosmos Holdings, commented, "This acquisition allows us to penetrate the growing osteoporosis drug market with potentially superior products that uniquely target the intestinal microbiome for skeletal health. This a strategic step, following the R&D partnership with Cloudpharm, towards building a competitive portfolio targeting the gut microbiome, which is vital in many diseases involving bone loss. Probiotics, prebiotics, and dietary supplements have been suggested to protect bone health by altering the composition of the gut microbiota. LIFE NLB's product portfolio contains unique formulations of prebiotics, which are believed to lead to better absorption and bioavailability. We are excited to leverage LIFE NLB's products through our established worldwide distribution network."
About Life NLB, Ltd.
LIFE NLB Ltd. develops, imports, and distributes unique nutritional supplements and medical devices operating in Greece. It was founded in 2016 and has developed partnerships with European companies such as Enzymatica, Eubage, Bitop AG and local Greek companies such as Theracell, Cloudpharm, Cana Laboratories in addition to Academic Institutions such as the National Hellenic Research Foundation, Athens Medical School LMRS, and the University of West Attica.
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. (Nasdaq:COSM) is an international pharmaceutical company, with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices through an extensive, established EU distribution network. The Company identifies, acquires, develops and commercializes products that improve patients' lives and outcomes. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: COSM@crescendo-ir.com
SOURCE: Cosmos Holdings, Inc.
View source version on accesswire.com:
https://www.accesswire.com/707689/Cosmos-Holdings-to-Acquire-LIFE-NLB-Portfolio-of-Bone-Health-Products-that-Target-the-Gastrointestinal-Microbiome
FAQ
What products does Cosmos Holdings acquire from LIFE NLB?
What is the significance of Bone-Vio® in osteoporosis treatment?
When are the clinical trial results for Bone-Vio® expected?
What is the current market valuation for the osteoporosis drug market?
